A recent study explored 168 prostate cancer patients undergoing androgen deprivation therapy and showed that those positive for AR-V7 expression (19%), compared to AR-V7-negative patients, exhibited lower prostate-specific antigen response rates to androgen deprivation, a much shorter time to castration-resistant prostate cancer, and lower cancer-specific and overall survival [219]. This evidence concerns the gene AR and prostate carcinoma.